The generation, activation, and polarization of monocyte-derived macrophages in human malignancies

Front Immunol. 2023 Apr 18:14:1178337. doi: 10.3389/fimmu.2023.1178337. eCollection 2023.

Abstract

Macrophages are immune cells that originate from embryogenesis or from the differentiation of monocytes. They can adopt numerous phenotypes depending on their origin, tissue distribution and in response to different stimuli and tissue environment. Thus, in vivo, macrophages are endowed with a continuum of phenotypes that are rarely strictly pro-inflammatory or anti-inflammatory and exhibit a broad expression profile that sweeps over the whole polarization spectrum. Schematically, three main macrophage subpopulations coexist in human tissues: naïve macrophages also called M0, pro-inflammatory macrophages referred as M1 macrophages, and anti-inflammatory macrophages also known as M2 macrophages. Naïve macrophages display phagocytic functions, recognize pathogenic agents, and rapidly undergo polarization towards pro or anti-inflammatory macrophages to acquire their full panel of functions. Pro-inflammatory macrophages are widely involved in inflammatory response, during which they exert anti-microbial and anti-tumoral functions. By contrast, anti-inflammatory macrophages are implicated in the resolution of inflammation, the phagocytosis of cell debris and tissue reparation following injuries. Macrophages also play important deleterious or beneficial roles in the initiation and progression of different pathophysiological settings including solid and hematopoietic cancers. A better understanding of the molecular mechanisms involved in the generation, activation and polarization of macrophages is a prerequisite for the development of new therapeutic strategies to modulate macrophages functions in pathological situations.

Keywords: CSF-1; LAM; TAM; differentiation; monocyte-derived macrophages; polarization; targeting macrophages.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents / pharmacology
  • Humans
  • Macrophages*
  • Monocytes
  • Neoplasms* / metabolism
  • Phagocytosis

Substances

  • Anti-Inflammatory Agents

Grants and funding

This work was supported by INSERM, the “Investments for the Future” Labex Signalife (ANR-11-LABX-0028-01), ITMO cancer (2019–2023), the ARC Foundation. EK is supported by a fellowship from Ligue Nationale Contre le Cancer. PA team is also supported by grants from ARC Foundation (Equipe labellisée 2022-2025), the ALF association (2021–2022), and INCA (PLBIO-2019-133). PA, AJ and GR are member of the OPALE Carnot institute.